Search results

Aims to evaluate the determinants of international pharmaceutical firms’ foreign direct investments (FDI) in the Chinese pharmaceutical manufacturing industry. Focuses on comparing the differences in FDIs between early entrants who started FDI before 1992 and the late entrants whose FDI started after 1992 in China. Field research was mainly conducted in China by personal interview as well as mail questionnaires over a period of three months in 1999 and 44 companies participated in total. The results of index of dissimilarity analysis, t‐test and Wilcoxon test consistently show that both early and late entrants are likely to agree that China’s huge market size played the most important role in motivating international pharmaceutical firms’ FDI in China. The results did not support the traditional FDI theories on domestic market imperfection and firm specific advantages.

The purpose of this paper is to analyze the Chinese pharmaceutical sector through three levels: policy level, enterprise level, and technology level.

The authors explore the environmental impacts, which include political, social, and economic factors, study enterprise‐level strategies on international technology transfer and carry out a trend analysis on the technology development in the Chinese pharmaceutical industry.

The results indicate that China is emerging in the biopharmaceutical industry. While there are several steps to be taken at different levels, including policy, enterprise, and technology, the country is presenting a potential for the future. The paper outlines the gaps in each area.

The paper provides a very good outline against which any emerging economy could review its potential in the pharmaceutical industry.

The purpose of this paper is to study how local government policy influences the structure of Chinese pharmaceutical clusters during their industrial catch-up.

This paper applies a case study method by targeting pharmaceutical clusters in Tonghua, Taizhou, and Tianjin.

The varied structures of pharmaceutical clusters in China demonstrate local governments' efforts to utilize local resources accordingly. While the local governments in China introduce different policies to firms with different ownership in the process of constructing different cluster composition, all the local governments emphasize motivating the development of small- and middle-sized enterprises for cluster dynamics.

The local governments should try to reach a balance between short-term foundation and long-term competitiveness for industrial cluster development.

This paper provides the detailed analysis of local governments' influences on the formation of pharmaceutical clusters in China and helps to enrich the knowledge about how local government promotes industrial clusters to realize industrial catch-up through sectoral innovation system.

This paper aims at discovering the opportunities and challenges for China's pharmaceutical industry (pharma) in technological, management and products innovation and thinking of the strategies for the industrial development based on thinking for high‐tech to create the future.

The study is primarily based on the literature review, data collection and interviews in varied research institutions, colleges as well as corporations. The literature review pays close attention to pharmaceutical industry and management. And the interviews took place in person, by telephone and via face‐to‐face conversations. By means of studying on the resulting data, this archive develops somewhat policy implications which can probably contribute to renew the competitiveness of China's pharmaceutical industry in innovation.

The critical shortages and the difficulties of China's pharmaceutical industry for development have been deeply discussed in this study, such as outdated healthcare system, controversial intellectual property regulation, and unconfident data system, which can handicap China's innovation.

This paper presents a systematic analysis of China's pharma, through addressing most key aspects, which is committed to driving incentives towards genuine innovation, and to sharing the potential competitive market. The findings of the dynamic health innovation system and the policy implications should be an original comprehensive understanding, all of which might be of interests to China's scholars, government officials and company practicing managers.

To investigate the impact of knowledge-intensive FDI in the Chinese pharmaceutical industry, this study analyzes the activity of foreign MNEs operating in this context by exploring their innovative background, the organizational arrangements they use for local knowledge creation and the performance of their local innovative processes. Based on the analysis of the universe of USPTO pharmaceutical patents applied for between 1975 and 2010 and granted to foreign assignees utilizing the work of Chinese inventors, our results show that, while the presence of foreign MNEs in the Chinese pharmaceutical industry entails a strong potential for positive externalities that could enhance the performance of the local innovation system, such externalities do not completely materialize yet, likely because of local actors’ limited absorptive capacity.

China was the only developing country that participated in the human genome project and contributed 1 per cent of human genome sequencing in 2000. And it finished rice genome sequencing independently in 2002. China’s biomedical industry, however, remains largely an academic affair. The industry is characterized by its inability to support and commercialize innovative research, which in turn has resulted in the prevalence of generic drugs. Managers of Chinese firms have been focusing on the shortterm profits that can be generated by generics rather than the longer‐term potential profits arising from innovative research. But the viability of such short‐cut strategy is now called into question as the IPR infringements will mean hefty fines to the violators in the wake of China’s WTO accession. There is hence an urgent need to make the timely transformation from academic affair to commercialization. This paper examines the reasons why biomedical industry remains largely an academic affair in China by stacking China against the key success factors of biomedical industry in the world. It then suggests the ways to make the transformation by filling the gap between basic research and commercial products and cultivating the necessary business environment for biomedical drugs in China.

The purpose of this paper is to explore patterns as well as determinants of regional specialisation in China's biopharmaceutical industry. It identifies and characterizes different types of enterprises engaged in the biopharmaceutical sector in terms of their business organisation and regional set up.

Based on data compilations not yet employed in academic analysis as well as personal interviews in China, structural determinants and driving forces of development are analysed against the background of the innovation systems literature.

The geography of innovation in China's biopharmaceutical industry is determined by both, government policy and the strategic location decisions of entrepreneurs. While local‐government support of firm clustering has contributed to a dispersion of industrial activity throughout China, the firms” networks are spanning clusters. Effectively, domestic firms are turning into multi‐regional companies locating activities such as R&D and manufacturing at different clusters.

The paper adds to the literature in so far as it throws light on an until now under‐researched field of China's innovation system. It identifies the concept of multi‐regionalism among domestic non‐state enterprises as an important parameter for understanding success and regional distribution of the industry.

The purpose of this paper, focusing mainly on India – and a lesser extent on China – is to examine, broadly, two related issues concerning the rise of pharmaceutical industry in the emerging economies: the strategic response of the emerging‐country pharmaceutical firms to the new patent regime that recognizes and enforces product patents; and its implications for multinational enterprise (MNE) strategies.

The paper is based on extensive review of the relevant conceptual and empirical literature and secondary data.

The strategic response of pharmaceutical firms in the emerging economies (India and China, for example,) to the new patent regime is to develop multiple competencies and position themselves to simultaneously compete and collaborate globally with the MNEs – large firms rapidly moving towards discovery and development of new drugs, and medium and small firms engaged in the production of off‐patent generics and contract manufacturing, respectively.

The trend towards greater collaboration between the emerging‐country firms and the MNEs in the new patent regime raises serious concern about prescription drug prices in the developing as well as developed countries. Given the importance of the pharma industry to the health of nations, firms in rich and poor countries alike will continue to come under public pressure to develop and market the needed drugs at affordable prices.

The paper would be of value to practitioners and scholars interested in the implications – for MNE pricing, outsourcing and R&D strategies, for example – of the rapid rise of pharmaceutical industry in the developing countries such as India and China.

Based on literature review, the purpose of this paper is to design a comprehensive evaluation system for pharmaceutical industry from the financial perspective, and then analyses the development strategy of Chinese pharmaceutical industry according to the data of listed companies.

This paper analyses the development strategy of Chinese pharmaceutical industry through building the grey dominance evaluation model including absolute degree of grey incidence model and relative degree of grey incidence model.

Through the analysis of the grey dominance evaluation model, the authors find that four factors including total assets turnover, quick ratio, inventory turnover and current ratio can be grouped into first grade assessment indicator when evaluating the performance of Chinese pharmaceutical industry. These four indexes contain the concept of operational efficiency which shows that operation capability is the key to support the development of Chinese pharmaceutical industry, needing to be highly valued when organizations making business policy. When it comes to velocity of development, the contribution of R & D intensity is relatively small, which shows innovation ability of China’s pharmaceutical industry is still weak. Innovation is the lifeblood of enterprise development, needing to be improved to promote enterprise’s core competitiveness in the future development.

This paper selects Y1-Y7 as the performance evaluation system of pharmaceutical manufacturing enterprises, while X1-X15 as performance evaluation index system from the financial perspective, which indicated that the evaluation system is scientific and practical. The empirical result shows that the operation capability makes the largest contribution to the performance of China’s pharmaceutical industry, while R & D ability and the enterprise core competitive ability are weak.

The pharmaceutical industry in the People’s Republic of China (PRC) has been highly regulated, particularly ethical products. Promulgation of the socialist market economy and the recent reforms in national healthcare industry have compelled impetuses for change in the distribution systems, forms of investment of multinational pharmaceutical companies, and product/market strategies. The conventional wisdom on pioneer marketing may be challenged by these situations in the PRC. This study examines four markets that encompass both specialty and general pharmaceuticals so as to explore whether there is a product category effect on entry strategies. The findings indicate a possible synergistic effect of product category and order of entry. In addition, product life cycle has a direct impact on order of entry whereas brand position has an effect on product category. Both government policies and corporate strategies have implications on product categories and order of entry. The recent reforms in China have helped to build a foundation for pharmaceutical companies to conduct business in a manner that is similar to that of the developed countries. The entry strategies for pharmaceuticals may therefore involve more complicated considerations in accordance with these new arrangements in the legal and regulatory environments. Further research into relationships among these variables and the mediation effect is therefore indicated.